Lab guide · Growth-hormone axis
What Is Ipamorelin? Ghrelin-Receptor Agonist Peptide Research Overview
What is Ipamorelin? It is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, that activates the ghrelin receptor (GHS-R1a) and was described in 1998 as a selective growth hormone secretagogue. This guide covers its structure, receptor pharmacology, how it differs from related peptides and what the evidence shows.
Key takeaways
- Ipamorelin is a pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, with the formula C38H49N9O5 and a molecular weight of 711.9 g/mol.
- It acts as an agonist at the ghrelin receptor, GHS-R1a, and was developed under the code NNC 26-0161.
- Raun et al. (1998) described it as the first GHRP-receptor agonist with a selectivity for GH release similar to that of GHRH.
- It contains non-standard residues (Aib, D-2-Nal, D-Phe), so identity testing must check stereochemistry as well as mass.
What is Ipamorelin?
So, what is Ipamorelin? Ipamorelin is a synthetic pentapeptide and ghrelin mimetic. PubChem describes it as binding the ghrelin receptor, also called the growth hormone secretagogue receptor (GHSR), and stimulating growth hormone release from the pituitary (PubChem). Its development code is NNC 26-0161.
Research use only. This overview summarises published laboratory and animal research. Baltic Peptides supplies this compound for in-vitro and preclinical research by qualified researchers; it is not a medicine and is not for human or veterinary use.
Chemical structure and specifications
| Property | Value |
|---|---|
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Length | 5 residues, C-terminal amide |
| Molecular formula | C38H49N9O5 |
| Molecular weight | 711.9 g/mol (average); 711.386 Da monoisotopic, calculated |
| CAS number | 170851-70-4 |
| PubChem CID | 9831659 |
These values match the PubChem record. Three non-standard features define it. Aib (2-aminoisobutyric acid) is at position 1, D-2-naphthylalanine at position 3 and D-phenylalanine at position 4. It contains no cysteine, methionine or tryptophan, so it lacks the most oxidation-prone residues.
Discovery and research history
Raun et al. (1998, Eur J Endocrinol) described ipamorelin as the first selective growth hormone secretagogue. In their conclusion, it is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH. The compound was derived from the growth hormone-releasing peptide family but optimised for narrower activity.
A pharmacokinetic-pharmacodynamic study in human volunteers followed (Pharm Res, 1999). Beyond that early work, the published human record is limited.
Mechanism: GHS-R1a agonism
Receptor and signalling
Ipamorelin binds GHS-R1a, a G protein-coupled receptor on pituitary somatotrophs. Activation couples through Gq/11 to intracellular calcium and GH secretion. This is the same receptor activated by the endogenous hormone ghrelin.
Selectivity
The original work compared ipamorelin with GHRP-6 in rat pituitary cells and animals, and its reported distinction is a narrower endocrine profile, with less effect on other pituitary hormones than earlier GHRPs. Selectivity is a pharmacological finding in the models used, not a safety conclusion.
Main research areas
- Receptor pharmacology: GHS-R1a binding, Gq/11 signalling and calcium assays in pituitary cell models.
- Selectivity benchmarking: comparison with GHRP-2, GHRP-6 and other ghrelin mimetics.
- GH axis studies: somatotroph responsiveness, GH pulse characteristics and IGF-1 downstream.
- Combination designs: studies pairing a GHRH analogue with a GHS-R1a agonist.
What published studies actually show
| Evidence type | What is reported |
|---|---|
| Chemical facts | Sequence, formula, mass and CAS number are database-verifiable. |
| Cell studies | GHS-R1a agonism and GH release in rat pituitary cells. |
| Animal studies | GH release in rats and swine, compared with GHRP-6. |
| Human research | An early pharmacokinetic and pharmacodynamic study in volunteers; no approved indication is known. |
| Unconfirmed | Long-term effects, and any benefit outside experimental settings. |
Most of the primary pharmacology dates from the late 1990s, so recent independent replication is limited.
Scientific limitations and open questions
- The core pharmacology rests on a 1998 paper and a small number of follow-ups.
- Selectivity was shown in the specific models and doses tested.
- Human data are limited, and no approved indication is known.
- GH-releasing peptides are covered by section S2 of the WADA Prohibited List.
- Receptor desensitisation and long-term effects are not well characterised in the sources reviewed here.
Analytical and laboratory considerations
The two D-residues matter analytically: an L-isomer at either position has the same mass but different receptor activity, so reverse-phase HPLC should resolve diastereomeric impurities. Mass spectrometry should show the intact pentapeptide at about 711.9 Da, including Aib and the C-terminal amide.
With no oxidation-prone residues it is relatively robust, but standard cold, dry storage still applies. See how to store peptides and the guide to reading a peptide COA. Batch reports are on the COA page, and formats are on the Ipamorelin product page.
Sources and further reading
- Raun K. et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 139(5):552-561. PubMed
- Pharmacokinetic-pharmacodynamic modelling of ipamorelin in human volunteers. Pharm Res 16(9):1412-1416 (1999). PubMed
- PubChem compound record for ipamorelin (CID 9831659). PubChem
- WADA Prohibited List, section S2. WADA
All Baltic Peptides products are supplied strictly for laboratory research use. They are not medicines, supplements or food and are not for human or animal use. This article summarises published research for educational purposes only and does not describe any use in people.
FAQ
Common questions
What is Ipamorelin?
What is the sequence of Ipamorelin?
What is the molecular weight and CAS number of Ipamorelin?
Which receptor does Ipamorelin act on?
Why was Ipamorelin called a selective growth hormone secretagogue?
How is Ipamorelin different from Sermorelin and CJC-1295?
Is Ipamorelin an approved medicine?
Keep reading
Related reading
Ipamorelin
Current batches, formats and the COA for Ipamorelin.
What is CJC-1295 No DAC?
The GHRH-receptor analogue most often studied alongside ipamorelin.
Peptide blends explained
Why component research does not define a combined formulation.
Research-grade Ipamorelin, tested before it ships
Independent HPLC and mass spec results for every batch, dispatched from the EU.
